EG17859A - Process for preparing of spiro-imidazolines as aldose reductase inhibitors - Google Patents

Process for preparing of spiro-imidazolines as aldose reductase inhibitors

Info

Publication number
EG17859A
EG17859A EG317/86A EG31786A EG17859A EG 17859 A EG17859 A EG 17859A EG 317/86 A EG317/86 A EG 317/86A EG 31786 A EG31786 A EG 31786A EG 17859 A EG17859 A EG 17859A
Authority
EG
Egypt
Prior art keywords
spiro
imidazolines
preparing
reductase inhibitors
aldose reductase
Prior art date
Application number
EG317/86A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG17859A publication Critical patent/EG17859A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EG317/86A 1985-05-29 1986-05-28 Process for preparing of spiro-imidazolines as aldose reductase inhibitors EG17859A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/738,924 US4575507A (en) 1985-05-29 1985-05-29 Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use

Publications (1)

Publication Number Publication Date
EG17859A true EG17859A (en) 1991-11-30

Family

ID=24970055

Family Applications (1)

Application Number Title Priority Date Filing Date
EG317/86A EG17859A (en) 1985-05-29 1986-05-28 Process for preparing of spiro-imidazolines as aldose reductase inhibitors

Country Status (21)

Country Link
US (1) US4575507A (es)
EP (1) EP0203791B1 (es)
JP (1) JPS61277671A (es)
KR (1) KR890001548B1 (es)
AT (1) ATE46332T1 (es)
AU (1) AU560429B2 (es)
DD (5) DD264213A5 (es)
DE (1) DE3665584D1 (es)
DK (1) DK248886A (es)
EG (1) EG17859A (es)
ES (2) ES8800228A1 (es)
FI (1) FI862251A (es)
GR (1) GR861388B (es)
HU (4) HU196060B (es)
IL (1) IL78954A (es)
NO (1) NO862123L (es)
NZ (1) NZ216334A (es)
PH (1) PH22213A (es)
PL (5) PL147400B1 (es)
PT (1) PT82650B (es)
ZA (1) ZA863934B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
WO1988006887A1 (en) * 1987-03-20 1988-09-22 Alcon Laboratories, Inc. Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus
US5202339A (en) * 1987-08-28 1993-04-13 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US5004751A (en) * 1987-08-28 1991-04-02 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
WO1990002126A1 (en) * 1988-08-24 1990-03-08 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US5068332A (en) * 1990-10-12 1991-11-26 American Home Products Corporation Alkylidene analogs of 1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones useful as aldose reductase inhibitors
US8326636B2 (en) * 2008-01-16 2012-12-04 Canyon Ip Holdings Llc Using a physical phenomenon detector to control operation of a speech recognition engine
CN104080775A (zh) * 2012-02-09 2014-10-01 勃林格殷格翰国际有限公司 立体选择性合成1,4-保护的9-羟基-5-氧代-1,4-二氮杂-螺[5.5]十一烷的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117230A (en) 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
CA1088945A (en) * 1976-10-18 1980-11-04 Pfizer Limited Hydantoin derivatives as therapeutic agents
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4248882A (en) * 1980-02-12 1981-02-03 Pfizer Inc. Treating diabetes-associated complications with hydantoin amines
JPS5745185A (en) * 1980-07-21 1982-03-13 Eisai Co Ltd Hydantoin derivative and its preparation
ATE23046T1 (de) * 1982-11-10 1986-11-15 Pfizer Sorbinil durch optische aufspaltung mit aminopinanderivaten.
ZA839023B (en) * 1982-12-06 1985-07-31 Pfizer Spiro-3-hetero-azolones for treatment of diabetic complications
US4556670A (en) 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
DE3561198D1 (en) * 1984-03-23 1988-01-28 Pfizer Spiro-indenes and spiro-1,2-dihydro-naphthalenes for treatment of diabetic complications
US4762838A (en) 1985-08-30 1988-08-09 Pfizer Inc. Quinazolin-4(3H)-one derivatives as anticoccidial agents

Also Published As

Publication number Publication date
PL266365A1 (en) 1988-03-03
EP0203791A1 (en) 1986-12-03
ES8801830A1 (es) 1988-02-16
AU560429B2 (en) 1987-04-09
JPS61277671A (ja) 1986-12-08
HU893127D0 (en) 1990-01-28
ES555375A0 (es) 1987-11-01
HU199845B (en) 1990-03-28
NO862123L (no) 1986-12-01
ES557391A0 (es) 1988-02-16
ZA863934B (en) 1988-01-27
FI862251A (fi) 1986-11-30
PL147399B1 (en) 1989-05-31
PL147400B1 (en) 1989-05-31
AU5801286A (en) 1987-01-08
DD264213A5 (de) 1989-01-25
ES8800228A1 (es) 1987-11-01
PL266364A1 (en) 1988-03-03
HUT44767A (en) 1988-04-28
NZ216334A (en) 1988-08-30
FI862251A0 (fi) 1986-05-28
DD264214A5 (de) 1989-01-25
DK248886A (da) 1986-11-30
EP0203791B1 (en) 1989-09-13
KR860008984A (ko) 1986-12-19
ATE46332T1 (de) 1989-09-15
PT82650A (en) 1986-06-01
PL266366A1 (en) 1988-03-03
DD273258A5 (de) 1989-11-08
PL146020B1 (en) 1988-12-31
HUT49882A (en) 1989-11-28
PL147397B1 (en) 1989-05-31
HU196060B (en) 1988-09-28
DK248886D0 (da) 1986-05-28
KR890001548B1 (en) 1989-05-08
GR861388B (en) 1986-09-17
PH22213A (en) 1988-06-28
PL147398B1 (en) 1989-05-31
DD264215A5 (de) 1989-01-25
DD251972A5 (de) 1987-12-02
IL78954A (en) 1989-09-28
IL78954A0 (en) 1986-09-30
PL266363A1 (en) 1988-03-03
US4575507A (en) 1986-03-11
HUT49879A (en) 1989-11-28
DE3665584D1 (de) 1989-10-19
PT82650B (pt) 1988-11-30

Similar Documents

Publication Publication Date Title
CA1260471C (es)
HU908076D0 (en) Process for producing amino acid derivatives
PH22520A (en) Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
ES2057126T3 (es) Metodo de tratamiento de la caquexia y algunos nuevos compuestos para utilizar en este metodo.
EG17859A (en) Process for preparing of spiro-imidazolines as aldose reductase inhibitors
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
PH24139A (en) Method of treating anxiety with tetrahydrobenzy(c,d)indole-6-carboxamides
AU6216886A (en) Substituted 2-cyano-2-phenyl ethyl-amine
HUT46043A (en) Process for producing immunstimulant acyltripeptides
GR3019893T3 (en) Novel S-adenosyl methionine decarboxylase inhibitors
HUT46214A (en) Process for producing medical preparation suitable for treatment of peptic ulcer
DE3167347D1 (en) New benzothiazine derivatives, processes for preparation thereof and use thereof
DE69504392D1 (de) Verwendung von Trovafloxacin oder dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung von H.Pylori Infektionen
HU912567D0 (en) Preparation for decreasing uric acid contain in blood
ES542811A0 (es) Un procedimiento para la preparacion de acidos pirrilidinpropanoicos.